Long‐Term Glucagon‐Like Peptide 1 Receptor Agonist Use Is Not Associated With Increased Risk of Thyroid Cancer in Adults With Type 2 Diabetes

Documenti analoghi

• Effects of Glucagon‐Like Peptide‐1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta‐Analysis
  di: Hee‐Ju Kim, et al.
  Pubblicazione: (2024)
• Earlier Menopause and Risk of Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Global Cohort Study
  di: Joshua Stokar, et al.
  Pubblicazione: (2026)
• Comparison of Sodium‐Glucose Cotransporter 2 Inhibitors Versus Glucagon‐Like Peptide‐1 Receptor Agonists and Risks of Osteoarthritis and Arthroplasty in Patients With Type 2 Diabetes Mellitus: A Propensity Score‐Matched Cohorts Retrospective Study
  di: Yu‐Chi Su, et al.
  Pubblicazione: (2025)
• Kidney Outcomes With Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Glucose‐Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta‐Analysis of Real‐World Data
  di: Alisa Fishkin, et al.
  Pubblicazione: (2025)
• Searching the Crystal Ball for Tailored GLP‐1 Receptor Agonists Treatment in Type 2 Diabetes and Obesity
  di: Asia Saturnino, et al.
  Pubblicazione: (2024)